LeMaitre Vascular Inc
NASDAQ:LMAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (11.1), the stock would be worth $93.74 (17% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.3 | $112.4 |
0%
|
| 3-Year Average | 11.1 | $93.74 |
-17%
|
| 5-Year Average | 10.5 | $88.69 |
-21%
|
| Industry Average | 5.2 | $43.62 |
-61%
|
| Country Average | 6.5 | $55.15 |
-51%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
LeMaitre Vascular Inc
NASDAQ:LMAT
|
2.6B USD | 13.3 | 44.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 24 | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 6.4 | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 8.3 | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 5.4 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 6.7 | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 9 | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 5.2 | 18.7 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 17.2 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 5.8 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 9.3 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.2 |
| Median | 6.5 |
| 70th Percentile | 10.6 |
| Max | 1 764 211.7 |
Other Multiples
LeMaitre Vascular Inc
Glance View
LeMaitre Vascular Inc., a company engaged in the innovation and marketing of devices for vascular surgeons, traces its roots back to a family enterprise founded on the values of craftsmanship and precision. The company was established in 1983 by George LeMaitre, a preeminent vascular surgeon whose legacy continues to resonate within its core operations. Headquartered in Burlington, Massachusetts, LeMaitre Vascular specializes in developing and selling a variety of products designed to treat peripheral vascular disease. This encompasses conditions that affect blood vessels outside the heart and brain, such as aortic aneurysms and varicose veins. With devices like grafts, patches, and endovascular stent grafts, LeMaitre meets the need for effective surgical tools, facilitating procedures that enhance patient outcomes and surgical efficiency. The company generates revenue primarily through the sale and distribution of its diverse product line to hospitals and surgeons. LeMaitre Vascular leverages a direct sales model, hiring an adept sales force across the globe that builds strong relationships with clinicians. This direct approach is complemented by carefully selected distributors in regions less accessible by its direct sales teams. A key aspect of their strategy is constant innovation, where they thoughtfully assimilate advanced techniques and materials, frequently through strategic acquisitions of smaller firms with promising technologies. This dedication to development, alongside meticulous manufacturing processes, ensures that their offerings remain at the forefront of vascular surgery solutions, thereby sustaining financial growth and a robust competitive edge in a specialized market.